FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Investee Companies Gain Traction in US Medical Cannabis Space
- FinCanna’s royalty finance model could be a game changer for companies needing capital while operating in the U.S. medical cannabis space
- Pilot marketing program offering HIPAA-compliant point-of-sale solution and inventory tracking system launched in California’s medical cannabis marketplace
- The U.S. medical cannabis market is projected to grow at 11.8 percent CAGR through 2025 from $5.1 billion to an estimated $12.5 billion in 2025 (New Frontier Data)
FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF), a royalty company focused on becoming the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry, continues to gain momentum as it invests in top-tier cannabis-related companies. FinCanna’s royalty model is a viable capital solution for U.S. businesses in the licensed medical cannabis sector as the company invests capital for a percentage of future revenues. FinCanna president and CEO Andriyko Herchak notes that the royalty model has been very successful in other industries and brings a uniquely effective approach to funding issues plaguing the U.S. cannabis marketplace.
“Our royalty model allows operators and business owners to preserve their ownership stake, not diluting themselves as they would with typical equity financing,” Herchak stated in an interview with CFN Media (http://nnw.fm/ZGv4u). “Banks and federally regulated institutions are largely on the sidelines, so debt financing is difficult to find. Equity financing, as I mentioned earlier, often comes with unfavorable terms for the company. So, our royalty model fills a void in the market for companies needing capital while operating in the U.S. cannabis space.”
FinCanna’s royalty model benefits include flexibility to meet specific business needs, preservation of equity, alignment of economic interests, tax efficient protocol, timely access to capital and autonomy for the investee. FinCanna recently announced that its portfolio investee – ezGreen Compliance – is already onboarding multiple customers shortly after launching its pilot marketing program that focuses on complying with federal health privacy issues during point-of-sale and inventory procedures.
ezGreen Compliance helps its customers successfully navigate through state-by-state license, tax and compliance issues by ensuring that patients’ confidential data is being handled properly while meeting the Health Insurance Portability and Accountability Act (HIPAA) and state privacy laws, a news release states (http://nnw.fm/6plFr). ezGreen Compliance provides a proven, state-of-the-art enterprise compliance and point-of-sale software solution for licensed medical cannabis dispensaries and cultivators.
“ezGreen has made excellent progress in a very short amount of time in securing partnerships and putting itself in position to become an industry leader in the U.S. cannabis compliance category,” Herchak added. “With its proven pharma-grade compliance solution, we believe they will continue to gain momentum and establish themselves as a leader in their category.”
The FinCanna royalty portfolio includes investments in Cultivation Technologies, Inc. (“CTI”), which owns Coachella Manufacturing, one of the first companies to operate a legal solvent extraction facility for cannabis in California. CTI provides infrastructure, technology, manufacturing and branding to the legal medical cannabis industry, which includes premium medical cannabis products, concentrates and vape cartridges (http://nnw.fm/xKcX3). The company also owns six acres in Coachella, California, which is entitled for an 111,500 square foot facility featuring cultivation centers, manufacturing facilities, a testing lab, a distribution hub and a centralized processing center.
FinCanna’s third investment to date is in Refined Resin Technologies Inc., which is currently retrofitting a large, state-of-the-art medical cannabis extraction laboratory in Oakland, California. Refined Resin’s business will focus on extracting high quality cannabis distillate for white labeling services to licensed major brands and infused product manufacturers that do not have direct access to compliant production facilities (http://nnw.fm/nK9vR).
“The Refined Resin team has very deep connections in the distribution and retail markets and are themselves very effective brand developers and marketers,” Herchak noted. “Moreover, the potential capacity of the facility, and its ability to produce high value-add products bode well for the financial future of the enterprise and commensurately, outstanding value for FinCanna shareholders.”
FinCanna is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in the U.S. medical cannabis sector, with a distinct focus on California.
For more information, visit the company’s website at www.FinCannaCapital.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- FinCanna’s royalty finance model could be a game changer for companies needing capital while operating in the U.S. medical cannabis space
- Pilot marketing program offering HIPAA-compliant point-of-sale solution and inventory tracking system launched in California’s medical cannabis marketplace
- The U.S. medical cannabis market is projected to grow at 11.8 percent CAGR through 2025 from $5.1 billion to an estimated $12.5 billion in 2025 (New Frontier Data)
FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF), a royalty company focused on becoming the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry, continues to gain momentum as it invests in top-tier cannabis-related companies. FinCanna’s royalty model is a viable capital solution for U.S. businesses in the licensed medical cannabis sector as the company invests capital for a percentage of future revenues. FinCanna president and CEO Andriyko Herchak notes that the royalty model has been very successful in other industries and brings a uniquely effective approach to funding issues plaguing the U.S. cannabis marketplace.
“Our royalty model allows operators and business owners to preserve their ownership stake, not diluting themselves as they would with typical equity financing,” Herchak stated in an interview with CFN Media (http://nnw.fm/ZGv4u). “Banks and federally regulated institutions are largely on the sidelines, so debt financing is difficult to find. Equity financing, as I mentioned earlier, often comes with unfavorable terms for the company. So, our royalty model fills a void in the market for companies needing capital while operating in the U.S. cannabis space.”
FinCanna’s royalty model benefits include flexibility to meet specific business needs, preservation of equity, alignment of economic interests, tax efficient protocol, timely access to capital and autonomy for the investee. FinCanna recently announced that its portfolio investee – ezGreen Compliance – is already onboarding multiple customers shortly after launching its pilot marketing program that focuses on complying with federal health privacy issues during point-of-sale and inventory procedures.
ezGreen Compliance helps its customers successfully navigate through state-by-state license, tax and compliance issues by ensuring that patients’ confidential data is being handled properly while meeting the Health Insurance Portability and Accountability Act (HIPAA) and state privacy laws, a news release states (http://nnw.fm/6plFr). ezGreen Compliance provides a proven, state-of-the-art enterprise compliance and point-of-sale software solution for licensed medical cannabis dispensaries and cultivators.
“ezGreen has made excellent progress in a very short amount of time in securing partnerships and putting itself in position to become an industry leader in the U.S. cannabis compliance category,” Herchak added. “With its proven pharma-grade compliance solution, we believe they will continue to gain momentum and establish themselves as a leader in their category.”
The FinCanna royalty portfolio includes investments in Cultivation Technologies, Inc. (“CTI”), which owns Coachella Manufacturing, one of the first companies to operate a legal solvent extraction facility for cannabis in California. CTI provides infrastructure, technology, manufacturing and branding to the legal medical cannabis industry, which includes premium medical cannabis products, concentrates and vape cartridges (http://nnw.fm/xKcX3). The company also owns six acres in Coachella, California, which is entitled for an 111,500 square foot facility featuring cultivation centers, manufacturing facilities, a testing lab, a distribution hub and a centralized processing center.
FinCanna’s third investment to date is in Refined Resin Technologies Inc., which is currently retrofitting a large, state-of-the-art medical cannabis extraction laboratory in Oakland, California. Refined Resin’s business will focus on extracting high quality cannabis distillate for white labeling services to licensed major brands and infused product manufacturers that do not have direct access to compliant production facilities (http://nnw.fm/nK9vR).
“The Refined Resin team has very deep connections in the distribution and retail markets and are themselves very effective brand developers and marketers,” Herchak noted. “Moreover, the potential capacity of the facility, and its ability to produce high value-add products bode well for the financial future of the enterprise and commensurately, outstanding value for FinCanna shareholders.”
FinCanna is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in the U.S. medical cannabis sector, with a distinct focus on California.
For more information, visit the company’s website at www.FinCannaCapital.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
